

# Resource Summary Report

Generated by ASWG on Aug 9, 2026

## CD8a Monoclonal Antibody (53-6.7), FITC, eBioscience

RRID:AB\_464914

Type: Antibody

---

### Proper Citation

(Thermo Fisher Scientific Cat# 11-0081-81, RRID:AB\_464914)

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_464914](http://antibodyregistry.org/AB_464914)

**Proper Citation:** (Thermo Fisher Scientific Cat# 11-0081-81, RRID:AB\_464914)

**Target Antigen:** CD8a

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Applications: Flow  
Consolidation on 1/2020: AB\_464914, AB\_10111322

**Antibody Name:** CD8a Monoclonal Antibody (53-6.7), FITC, eBioscience

**Description:** This monoclonal targets CD8a

**Target Organism:** mouse

**Clone ID:** Clone 53-6.7

**Antibody ID:** AB\_464914

**Vendor:** Thermo Fisher Scientific

**Catalog Number:** 11-0081-81

**Record Creation Time:** 20251213T073652+0000

**Record Last Update:** 20260225T230828+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD8a Monoclonal Antibody (53-6.7), FITC, eBioscience.

No alerts have been found for CD8a Monoclonal Antibody (53-6.7), FITC, eBioscience.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Purbey PK, et al. (2024) Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity. Cell reports, 43(6), 114289.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer cell, 41(2), 235.

Pereira JA, et al. (2020) Mice carrying an analogous heterozygous dynamin 2 K562E mutation that causes neuropathy in humans develop predominant characteristics of a primary myopathy. Human molecular genetics, 29(8), 1253.

Turaj AH, et al. (2017) Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer cell, 32(6), 777.

Damgaard RB, et al. (2016) The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity. Cell, 166(5), 1215.